CPDC’s Radiopharmaceutical Manufacturing Facility Receives Clearance from FDA

January 9, 2020 CPDC

Hamilton, Ontario, Canada – January 9, 2020 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that, following a successful U.S. Food and Drug Administration (FDA) inspection in July, CPDC’s site in Hamilton, Ontario, is cleared to ship products to the U.S. 

Justyna Kelly, interim CEO of CPDC, stated, “We are delighted with the outcome of the FDA inspection. We look forward to continuing to support the clinical development efforts of our many global partners and we’re thankful for the excellent support from all of our staff.”

FDA’s inspection of CPDC closed with no 483 observations and was classified as NAI (No Action Indicated).

About CPDC

The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDCis a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.

Contacts

Centre for Probe Development and Commercialization
Angela Lauretani, 905 525-9140, ext. 21212
cpdc@imagingprobes.ca

More news from CPDC

CPDC Announces Appointment of Justyna Kelly as Permanent CEO

Hamilton, Ontario June 23, 2020 The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18, 2020. Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie, outgoing Chair of

ARTMS Closes a US$19 Million Series A Financing with Deerfield and Global Health Sciences (GHS) Fund

VANCOUVER, Canada and NEW YORK, United States, May 20, 2020 – ARTMS Inc. a global leader in developing technology that transforms the production of the world’s most-used diagnostic imaging isotopes, today announced that it has raised US$19 million in a Series A financing. The investment was led by New York based Deerfield Management Company with

Centre for Probe Development & Commercialization (CPDC) Appoints New Interim CEO

Hamilton, Ontario, December 3, 2019 – Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing as of today that the Company’s Board of Directors has appointed Justyna Kelly as Interim Chief Executive Officer effective immediately. Dr.  Joe McCann will stay on as an Advisor

For more information contact us at: